Want to see ATYR full AI Analyst Report?
Top Page
aTyr Pharma
(NASDAQ:ATYR)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.49
▲(4.47% Upside)
Action:Reiterated
Date:08/08/26
ATYR scores low primarily due to very weak financial performance driven by ongoing losses and significant cash burn, despite modest leverage. Technicals remain pressured by a longer-term downtrend and slightly negative momentum, while valuation offers limited support given a negative P/E and no dividend. Corporate events add uncertainty from Nasdaq compliance risk, only partly offset by progress toward a new Phase 3 trial.
Positive Factors
Balance Sheet Strength
Modest leverage and contained total debt reduce refinancing and interest-rate vulnerability versus peers. A stronger balance-sheet footing gives the company more optionality to fund a Phase 3 or secure partnerships without immediate heavy reliance on dilutive financings, supporting near-term program continuity.
Negative Factors
Persistent Cash Burn
Sustained negative operating and free cash flow erodes cash reserves and forces recurring capital raises. Long-term cash burn increases dilution risk, limits strategic flexibility to run pivotal trials independently, and heightens dependency on external funding or partnerships to progress development programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Modest leverage and contained total debt reduce refinancing and interest-rate vulnerability versus peers. A stronger balance-sheet footing gives the company more optionality to fund a Phase 3 or secure partnerships without immediate heavy reliance on dilutive financings, supporting near-term program continuity.
Read all positive factors
aTyr Pharma (ATYR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$54.83M
Dividend YieldN/A
Average Volume (3M)1.96M
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue GrowthN/A
EPS Growth21.92%
CountryUS
Employees58
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.62
Shares Outstanding98,087,425
10 Day Avg. Volume1,483,218
30 Day Avg. Volume1,963,911
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.08
Price to Sales (P/S)383.25
P/FCF Ratio-1.17
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.13Price Target Upside564.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.46
Revenue Forecast (FY)N/A
aTyr Pharma Business Overview & Revenue Model
Company Description
aTyr Pharma, Inc. (ATYR) is a clinical-stage biotechnology company focused on discovering and developing therapeutics based on immunological pathways associated with tRNA synthetases, aiming to address immune-mediated and inflammatory diseases. Th...
How the Company Makes Money
aTyr Pharma does not have publicly established, ongoing product sales; as a clinical-stage biotech, it typically generates little to no recurring commercial revenue. Available revenue, when present, is generally derived from (1) collaboration and ...
aTyr Pharma Earnings Call Summary
Earnings Call Date:Mar 13, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in clinical trials and market opportunities, along with a solid financial position. However, there are challenges related to limited clinical studies for benchmarking and high unmet medical needs in the current market landscape.Positive Updates
Completion of Enrollment in EFZO-FIT Phase 3 Study
aTyr completed enrollment in the global pivotal Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis, enrolling 268 patients across 85 centers in 9 countries.
Negative Updates
Limited Clinical Studies in Sarcoidosis
There are limited clinical studies in sarcoidosis to benchmark against, presenting challenges in pioneering a path forward for measuring improvements in this patient population.
Read all updates
Q4-2024 Updates
Positive
Negative
Completion of Enrollment in EFZO-FIT Phase 3 Study
aTyr completed enrollment in the global pivotal Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis, enrolling 268 patients across 85 centers in 9 countries.
Read all positive updates
Company Guidance
During aTyr Pharma's fourth quarter and full year 2024 conference call, the company provided comprehensive guidance on their clinical developments and strategic outlook. They highlighted the completion of enrollment in the pivotal Phase 3 EFZO-FIT study for efzofitimod, aimed at treating pulmonary sarcoidosis. This trial involves 268 patients across 85 centers in nine countries, testing doses of 3 mg/kg and 5 mg/kg against a placebo over 52 weeks, with a primary endpoint focused on steroid reduction. The company also noted that 75% of diagnosed sarcoidosis patients are prescribed steroids, with the U.S. patient population being 30% larger than previously estimated. Additionally, they have observed four positive data and safety monitoring board reviews with no safety concerns. Financially, aTyr ended 2024 with $75.1 million in cash, supplemented by $18.8 million from an ATM offering. They project their cash runway will last through a year following the Phase 3 readout. The company also discussed plans for commercial readiness and the potential for efzofitimod in a $2-5 billion ILD market, with sarcoidosis representing a significant portion.aTyr Pharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 190.00K | 190.00K | 235.00K | 353.00K | 10.39M | 0.00 |
| Gross Profit | -22.33M | -1.36M | 235.00K | 353.00K | 8.69M | -1.30M |
| EBITDA | -58.54M | -72.56M | -62.48M | -47.66M | -43.65M | -32.47M |
| Net Income | -60.81M | -74.12M | -64.02M | -50.39M | -45.34M | -33.77M |
Balance Sheet | ||||||
| Total Assets | 69.83M | 94.16M | 96.83M | 120.65M | 95.79M | 115.54M |
| Cash, Cash Equivalents and Short-Term Investments | 57.42M | 78.69M | 72.13M | 98.17M | 66.15M | 107.91M |
| Total Debt | 11.30M | 12.03M | 13.28M | 15.10M | 11.53M | 1.38M |
| Total Liabilities | 21.23M | 26.88M | 27.00M | 30.18M | 24.50M | 6.41M |
| Stockholders Equity | 48.79M | 67.48M | 70.02M | 90.66M | 71.46M | 109.30M |
Cash Flow | ||||||
| Free Cash Flow | -54.82M | -62.06M | -69.18M | -37.44M | -43.53M | -33.27M |
| Operating Cash Flow | -54.54M | -61.99M | -69.12M | -33.22M | -41.89M | -33.08M |
| Investing Cash Flow | 22.88M | -5.05M | 17.23M | -20.13M | 47.24M | -91.57M |
| Financing Cash Flow | 29.21M | 66.01M | 39.86M | 66.23M | 5.45M | 110.03M |
aTyr Pharma Technical Analysis
Positive
0.47
Price Trends
0.52
Positive
0.62
Negative
0.72
Negative
Market Momentum
<0.01
Negative
59.11
Neutral
67.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATYR, the sentiment is Positive. The current price of 0.47 is below the 20-day moving average (MA) of 0.51, below the 50-day MA of 0.52, and below the 200-day MA of 0.72, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 59.11 is Neutral, neither overbought nor oversold. The STOCH value of 67.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATYR.
aTyr Pharma Risk Analysis
aTyr Pharma disclosed 70 risk factors in its most recent earnings report. aTyr Pharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
aTyr Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $524.65M | -7.03 | -75.35% | ― | 220.34% | 55.73% | |
45 Neutral | $48.04M | -1.09 | -82.06% | ― | ― | -23.49% | |
43 Neutral | $79.77M | -6.36 | -200.67% | ― | ― | -39.90% | |
42 Neutral | $54.83M | -0.90 | -95.59% | ― | ― | 21.92% |
* Healthcare Sector Average
ATYR
aTyr Pharma
0.56
-4.35
-88.62%
XBIT
XBiotech
2.30
-0.90
-28.13%
PRLD
Prelude Therapeutics
5.55
4.61
490.43%
CNTX
Context Therapeutics
0.52
-0.35
-40.14%
OKYO
OKYO Pharma Limited Sponsored ADR
1.52
-0.89
-36.93%
aTyr Pharma Corporate Events
Business Operations and Strategy
aTyr Pharma Regains Global Rights to Efzofitimod
Neutral
Jul 31, 2026
On May 12, 2026, aTyr Pharma received notice from Kyorin Pharmaceutical that it would terminate their collaboration and license agreement covering efzofitimod in Japan, and on July 30, 2026 the parties signed a termination agreement that made the ...
Delistings and Listing ChangesRegulatory Filings and Compliance
aTyr Pharma Granted Nasdaq Extension to Regain Compliance
Negative
Jun 8, 2026
On December 4, 2025, aTyr Pharma, Inc. disclosed that it had received a Nasdaq deficiency notice because its common stock had closed below the $1.00 minimum bid price for 30 consecutive business days, though this notice did not immediately affect ...
Business Operations and Strategy
aTyr Pharma Refines Efzofitimod Strategy After Phase 2 Data
Negative
Jun 1, 2026
aTyr Pharma has updated investors on its strategy to advance efzofitimod, a novel NRP2-targeting biologic for inflammatory and fibrotic lung diseases, and to progress ATYR0101 for fibrosis through IND-enabling studies as part of its broader tRNA s...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
aTyr Pharma Announces New Phase 3 Sarcoidosis Trial
Positive
May 11, 2026
On May 11, 2026, aTyr Pharma reported a regulatory and clinical update on efzofitimod in pulmonary sarcoidosis after receiving minutes from a Type C meeting with the U.S. Food and Drug Administration. The agency’s feedback affirmed forced vi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.